Company intelligence / Profile preview
Xintela AB
Lund, Swedenxintela.se ↗
- Ownership
- Private
- Employees
- ~21
- Development stage
- Phase 1
01
Overview
Xintela has demonstrated safety and initial efficacy signals with its lead stem cell product XSTEM in Phase I/IIa trials for knee osteoarthritis. Other programs are at preclinical or early clinical stages. The company also develops antibody-based therapies targeting aggressive cancers such as triple-negative breast cancer and glioblastoma, currently at the preclinical stage.[1][3][5]
- Therapeutic areas
- PulmonologyDermatologyRheumatologyOncology
- Modalities
- Stem cell therapy (e.g., mesenchymal stem cells)Antibody-based therapies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Agreement with Region Östergötland for GMP process development of cell therapy for burn patients[3]
Beyond the preview
Go deeper on Xintela AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xintela AB.